Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 May;89(5):583-8.
doi: 10.1111/j.1349-7006.1998.tb03301.x.

Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vivo

Affiliations

Effect of gelonin immunoconjugate with monoclonal antibody MSN-1 to endometrial adenocarcinoma on antigen-producing tumor cells in vivo

Y Kaneta et al. Jpn J Cancer Res. 1998 May.

Abstract

Missile therapy, which destroys cancer cells specifically, has been advocated as an effective modality for the treatment of carcinoma. We have developed an immunoconjugate consisting of the monoclonal antibody MSN-1 (IgM), which reacts strongly with endometrial adenocarcinomas, combined with a plant hemitoxin named gelonin via a disulfide bond using N-succinimidyl-3-(2-pyridyldithio) propionate and 2-iminothiolane, and examined its selective cytotoxicity in athymic mice. The reductions in resected weights of target tumor cells, at the local site of MSN-1-gelonin immunoconjugate treatment, were 96% with local administration and 75% with caudal vein administration, as compared with the untreated group. There was no weight loss in treated mice. Our results suggest that this MSN-1-gelonin immunoconjugate has potential clinical applications in the treatment of endometrial adenocarcinomas.

PubMed Disclaimer

Similar articles

Cited by

References

    1. ) Inoue , M. , Okayama , A. , Fujita , M. , Enomoto , T. , Tanizawa , O. and Ueshima , H.A case‐control study on risk factors for uterine endometrial cancer in Japan . Jpn. J. Cancer Res. , 85 , 346 – 350 ( 1994. ). - PMC - PubMed
    1. ) Brinkmann , U. , Di Carlo , A. , Vasmatzis , G. , Kurochkina , N. , Beers , R. , Lee , B. and Pastan , I.Stabilization of a recombinant Fv fragment by base‐loop interconnection and VH‐VL permutation . J. Mol. Biol. , 268 , 107 – 117 ( 1997. ). - PubMed
    1. ) Galun , E. , Shouval , D. , Adler , R. , Shahaar , M. , Hurwitz , E. and Sela , M.The effect of anti‐α‐fetoprotein‐adriamycin conjugate on a human hepatoma . Hepatology , 11 , 578 – 584 ( 1990. ). - PubMed
    1. ) Pai , L. H. , Batra , J. K. , FitsGerald , D. J. , Willingham , M. C. and Pastan , I.Anti‐tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin . Proc. Natl. Acad. Sci. USA , 88 , 3358 – 3362 ( 1991. ). - PMC - PubMed
    1. ) Nozawa , S. , Sakayori , M. , Takayama , Y. , Tsukazaki , K. , Aoki , D. , lizuka , R. , Mukai , M. and Inaba , N.Production of monoclonal antibody against a newly established human endometrial cancer cell line SNG‐II . Acta Obstet. Gynaecol. Jpn. , 39 , 559 – 566 ( 1987. ). - PubMed

Publication types

Substances

LinkOut - more resources